Vir Biotechnology, Inc. (NASDAQ:VIR) Insider Sells $900,000.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) insider Phillip Pang sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $30.00, for a total value of $900,000.00. Following the completion of the transaction, the insider now owns 144,000 shares in the company, valued at approximately $4,320,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Vir Biotechnology Trading Up 1.5 %

Vir Biotechnology stock traded up $0.46 during midday trading on Wednesday, hitting $30.84. 1,225,266 shares of the stock were exchanged, compared to its average volume of 768,736. The stock’s 50-day simple moving average is $26.39 and its 200 day simple moving average is $25.07. Vir Biotechnology, Inc. has a fifty-two week low of $18.05 and a fifty-two week high of $35.48. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of 3.49 and a beta of 0.15.

Vir Biotechnology (NASDAQ:VIRGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $0.01 by $1.29. The firm had revenue of $374.56 million during the quarter, compared to analysts’ expectations of $153.79 million. Equities analysts anticipate that Vir Biotechnology, Inc. will post 4.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE lifted its stake in shares of Vir Biotechnology by 175.1% in the 2nd quarter. US Bancorp DE now owns 982 shares of the company’s stock valued at $25,000 after purchasing an additional 625 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Vir Biotechnology by 127.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $25,000 after buying an additional 560 shares during the last quarter. Wipfli Financial Advisors LLC purchased a new position in Vir Biotechnology during the third quarter worth about $25,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Vir Biotechnology during the second quarter valued at about $36,000. Finally, Captrust Financial Advisors raised its stake in shares of Vir Biotechnology by 1,270.7% in the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock valued at $46,000 after acquiring an additional 1,690 shares during the period. 74.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. SVB Leerink increased their target price on shares of Vir Biotechnology from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Friday, November 4th. TheStreet upgraded shares of Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. Needham & Company LLC decreased their target price on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. Finally, Morgan Stanley upped their price target on Vir Biotechnology from $15.00 to $18.00 and gave the company an “underweight” rating in a research report on Friday, November 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $52.50.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.